In the STEP trials, semaglutide at 1.0 mg produced 13.2% weight loss
(Please note the bottle container is not full to the rim, the item is sold on weight basis)
There are two major histological subtypes, EAC and esophageal squamous cell carcinoma (ESCC)
Iijima T, Shibuya M, Ito Y, Terauchi Y (2023) Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: a randomized controlled trial
It has been shown that the liver is the main site to accumulate EGT, and a previous animal study found that supplementation of EGT [70 mg/kg body weight (bw)] in rats for 7 days before injection of ferric-nitrilotriacetate could protect the liver from the injury of lipid peroxidation (Sakrak et al., 2008)
While safety data is encouraging, with no significant differences in adverse events compared to placebo, a larger Phase IV outcomes trial is ongoing to confirm the long-term cardiovascular benefits of enlicitide, and Merck has initiated the FDA approval process, with the drug in the fast track program
